STOCKHOLM, April 23, 2020
STOCKHOLM, April 23, 2020 /PRNewswire/ -- Stronger focus on clinical projects
"The focusing of our operations protects the company's liquidity, but is also part of our long-term strategy with a emphasis on clinical projects and innovation," CEO Per Norlén comments.
Significant events January-March
Events after the end of the period
Read the complete report in the pdf below.
This information is such as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8:00 a.m. CEST on April 23, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com/.
For further information, please contact:
Per Norlén, CEO
Director IR & Communications
Alligator Bioscience AB (publ) 556597-8201
Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Alligator Bioscience AB (publ) Interim report January-March 2020